Boothbay Fund Management’s Ascendis Pharma A/S ASND Stock Holding History

Boothbay Fund Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-50	Closed	-$644K	–	1837
2021 Q1	$644K	Hold	50	–	–	0.02%	809
2020 Q4	$834K	Sell	50 -132	-73%	-$21.8K	0.03%	563
2020 Q3	$2.81M	Hold	182	–	–	0.17%	142
2020 Q2	$2.69M	Buy	+182	New	+$25K	0.18%	142
2020 Q1	–	Sell	-134	Closed	-$1.86M	–	846
2019 Q4	$1.86M	Sell	134 -70	-34%	-$7.78K	0.16%	168
2019 Q3	$1.97M	Hold	204	–	–	0.18%	148
2019 Q2	$2.35M	Buy	+204	New	+$24.4K	0.21%	121

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boothbay Fund Management's ASND Position: Q4 2025 in Review

Boothbay Fund Management sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 5,001 shares — an estimated $994K sold.

Boothbay Fund Management first reported a position in ASND in Q1 2019 and held it in 6 quarters. The position peaked at $2.73M in Q1 2019. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Boothbay Fund Management reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 5,001 Ascendis Pharma A/S shares in Q4 2025, an estimated $994K.
Boothbay Fund Management first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 6 quarters.
Boothbay Fund Management's Ascendis Pharma A/S position peaked at $2.73M in Q1 2019.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.